Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019;37(2):123-130.
doi: 10.1159/000493462. Epub 2018 Oct 10.

Pregnancy Outcomes of Patients Exposed to Adalimumab in Japan

Yumi Kawai  1 , Tsuyoshi Tsuchiya  2 , Shigeru Aoki  3
Affiliations

Pregnancy Outcomes of Patients Exposed to Adalimumab in Japan

Yumi Kawai et al. Dig Dis. 2019.

Abstract

Background: This is the first retrospective report of pregnancy outcomes after exposure to adalimumab treatment in Japan.

Methods: Using the AbbVie safety database, we analyzed pregnancy outcome data from patients who received adalimumab treatment from April 16, 2008, to May 15, 2017.

Results: Data were extracted retrospectively for 74 pregnancies in 73 patients. More than half of the patients included in the study received adalimumab for the treatment of Crohn's disease (37.8%) or ulcerative colitis (20.3%), while 9.5% received adalimumab for rheumatoid arthritis. Of the 53 pregnancies with available outcome data, 45 newborns (45/53 [84.9%]) were delivered. Of these births, 30 were full-term, 2 were preterm, and 13 were unknown. Apgar scores were available for 11 of the 16 newborns whose mothers were exposed to adalimumab in the third trimester; all scores were within the normal range. Low birth weight was observed in 5 infants out of the 30 full-term deliveries. There were also 5 miscarriages (5/53 [9.4%]), 2 induced abortions (2/53 [3.8%]), and 1 stillbirth (1/53 [1.9%]). Eight maternal adverse events were observed in 5 pregnancies; no serious adverse events occurred.

Conclusion: Although safety concerns were inconclusive, these data do not report additional risk to pregnancy outcomes with adalimumab exposure.

Keywords: Adalimumab; Inflammatory bowel disease; Pregnancy; Rheumatoid arthritis; Safety.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Summary of birth events.
See this image and copyright information in PMC

References

    1. Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A. Outcome of pregnancy and neonatal complications with anti-tumor ­necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun. 2017;76:38–52. - PubMed
    1. Doria A, Iaccarino L, Arienti S, Ghirardello A, Zampieri S, Rampudda ME, Cutolo M, Tincani A, Todesco S. Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol. 2006;22:234–241. - PubMed
    1. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1756–1767. - PMC - PubMed
    1. Yang CS, Teeple M, Muglia J, Robinson-Bostom L. Inflammatory and glandular skin disease in pregnancy. Clin Dermatol. 2016;34:335–343. - PubMed
    1. Østensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse ME, Costedoat-Chalumeau N, Cutolo M, Dolhain R, Fenstad MH, Förger F, Wahren-Herlenius M, Ruiz-Irastorza G, Koksvik H, Nelson-Piercy C, Shoenfeld Y, Tincani A, Villiger PM, Wallenius M, von Wolff M. State of the art: reproduction and pregnancy in rheumatic diseases. Autoimmun Rev. 2015;14:376–386. - PubMed